Participant flow

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma · Source last updated 2018-08-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.

   id

   FG000

   title

   Conventional & Patient-specific Dosimetry

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      tumors not visible on imaging

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      Conventional Dosimetry

   3. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      Patient-specific Dosimetry

   4. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

All NHL patients treated by either Bexxar or Zevalin

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice